--- title: "Tonix Pharmaceuticals Holding (TNXP) news: lawsuit" url: "https://aibio.space/companies/tonix-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "TNXP lawsuit news: Tonix gets Paragraph IV patent notice from Dr. Reddy's on generic TONMYA application. Tonix Pharmaceuticals Holding Corp." --- TNXP Tonix Pharmaceuticals Holding Corp. NASDAQ · United States # Tonix Pharmaceuticals Holding (TNXP) news TNXP lawsuit news Legal · 2026-10-02 ## [Tonix gets Paragraph IV patent notice from Dr. Reddy's on generic TONMYA application](https://aibio.space/news/tonix-gets-paragraph-iv-patent-notice-dr-reddys-generic-tonmya/) Dr. Reddy's told Tonix on October 1, 2026 that it filed an ANDA for a generic version of TONMYA 2.8 mg sublingual tablets and certified that four Orange Book patents are invalid, unenforceable or not infringed. No lawsuit has been filed, and Tonix says it intends to enforce its rights. ## Latest Tonix Pharmaceuticals Holding news 1. 2025-06-11 Financings [Tonix sets up programs to sell up to $150.0 million and $75.0 million of stock](https://aibio.space/news/tonix-sets-up-programs-sell-up-150-0-million-75-0-million-stock/) Tonix set up two ways to sell new stock on June 11, 2025: up to $150.0 million through A.G.P./Alliance Global Partners and up to $75.0 million to Lincoln Park Capital Fund. Its lead drug has an FDA decision date of August 15, 2025. ## Tonix Pharmaceuticals Holding at a glance - **Ticker**: TNXP - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $176.2 million ### Related companies - [MapLight Therapeutics](https://aibio.space/companies/maplight-therapeutics/) NASDAQ: MPLT - [Gossamer Bio](https://aibio.space/companies/gossamer-bio/) NASDAQ: GOSS - [TherapeuticsMD](https://aibio.space/companies/therapeuticsmd/) NASDAQ: TXMD - [ANTHERA PHARMACEUTICALS INC](https://aibio.space/companies/anthera-pharmaceuticals/) OTC: ANTH - [Adicet Bio](https://aibio.space/companies/adicet-bio/) NASDAQ: ACET - [Evommune](https://aibio.space/companies/evommune/) NYSE: EVMN - [Indaptus Therapeutics](https://aibio.space/companies/indaptus-therapeutics/) NASDAQ: INDP - [Latigo Biotherapeutics](https://aibio.space/companies/latigo-biotherapeutics/) NASDAQ: LTGO ### Also on NASDAQ - [Adicet Bio](https://aibio.space/companies/adicet-bio/) ACET - [Mineralys Therapeutics](https://aibio.space/companies/mineralys-therapeutics/) MLYS - [Upstream Bio](https://aibio.space/companies/upstream-bio/) UPB - [Kyntra Bio](https://aibio.space/companies/kyntra-bio/) KYNB - [Dare Bioscience](https://aibio.space/companies/dare-bioscience/) DARE - [CollPlant Biotechnologies](https://aibio.space/companies/collplant-biotechnologies/) CLGN ## What Tonix Pharmaceuticals Holding does Tonix Pharmaceuticals is a fully integrated biopharmaceutical company commercializing and developing innovative therapies for central nervous system disorders, immunology, infectious diseases and rare diseases. Its first internally developed product, TONMYA (cyclobenzaprine HCl sublingual tablets), was approved by the FDA in August 2025 for fibromyalgia in adults and launched on November 17, 2025. Tonix also markets two FDA-approved acute migraine products, Zembrace SymTouch (sumatriptan injection) and Tosymra (sumatriptan nasal spray). Its TNX-102 SL formulation is being explored in Phase 2 trials for major depressive disorder and acute stress disorder, and a Phase 2 study in major depressive disorder is expected to start in mid-2026. Other clinical programs include TNX-1500, a humanized antibody targeting CD40-ligand for kidney transplant rejection and autoimmune diseases, and TNX-1300, a cocaine esterase in Phase 2 for cocaine intoxication that holds Breakthrough Therapy designation. TNX-4800, a Lyme disease prevention antibody, and TNX-2900, for Prader-Willi syndrome, are also in its pipeline. | Product or program | What it is | Stage | |---|---|---| | TONMYA (cyclobenzaprine HCl sublingual tablets) | Non-opioid analgesic for fibromyalgia in adults | approved in the US | | Zembrace SymTouch (sumatriptan injection) | Acute migraine treatment | approved in the US | | Tosymra (sumatriptan nasal spray) | Acute migraine treatment | approved in the US | | TNX-102 SL | Cyclobenzaprine sublingual tablet explored for depression and stress disorders | Phase 2 | | TNX-1500 | Humanized antibody targeting CD40-ligand for transplant rejection and autoimmune diseases | Phase 2-ready | | TNX-1300 | Double-mutant cocaine esterase for cocaine intoxication | Phase 2 | Summarised from the company's [10-K filed Mar 12, 2026](https://www.sec.gov/Archives/edgar/data/1430306/000199937126005730/tnxp-10k_123125.htm). ## Tonix Pharmaceuticals Holding annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$13.1 million](https://www.sec.gov/Archives/edgar/data/1430306/000199937126005730/) | [$10.1 million](https://www.sec.gov/Archives/edgar/data/1430306/000199937126005730/) | | Research and development | [$44.5 million](https://www.sec.gov/Archives/edgar/data/1430306/000199937126005730/) | [$40.0 million](https://www.sec.gov/Archives/edgar/data/1430306/000199937126005730/) | | Net income (loss) | [-$124.0 million](https://www.sec.gov/Archives/edgar/data/1430306/000199937126005730/) | [-$130.0 million](https://www.sec.gov/Archives/edgar/data/1430306/000199937126005730/) | | Cash from operations | [-$99.8 million](https://www.sec.gov/Archives/edgar/data/1430306/000199937126005730/) | [-$60.9 million](https://www.sec.gov/Archives/edgar/data/1430306/000199937126005730/) | | Cash and equivalents | [$207.6 million](https://www.sec.gov/Archives/edgar/data/1430306/000199937126017452/) | [$98.8 million](https://www.sec.gov/Archives/edgar/data/1430306/000199937126005730/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $176.2 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Tonix Pharmaceuticals Holding Is Tonix Pharmaceuticals Holding involved in a lawsuit? Our latest story on this, dated Oct 2, 2026: "Tonix gets Paragraph IV patent notice from Dr. Reddy's on generic TONMYA application". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/tonix-gets-paragraph-iv-patent-notice-dr-reddys-generic-tonmya/). What is the ticker symbol of Tonix Pharmaceuticals Holding? Tonix Pharmaceuticals Holding Corp. trades under the ticker TNXP on NASDAQ. Where is Tonix Pharmaceuticals Holding listed? Tonix Pharmaceuticals Holding Corp. is listed on NASDAQ. Our directory also records these other listings: LS:A40VM0; LSX:A40VM0. What is the SEC CIK of Tonix Pharmaceuticals Holding? The SEC Central Index Key (CIK) for Tonix Pharmaceuticals Holding Corp. is 1430306. Its filings are on SEC EDGAR. How many shares does Tonix Pharmaceuticals Holding have outstanding? 17,151,024 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-10. Which country or territory is Tonix Pharmaceuticals Holding listed under? Our directory records Tonix Pharmaceuticals Holding Corp. under United States. What does Tonix Pharmaceuticals Holding do? Our directory classifies Tonix Pharmaceuticals Holding Corp. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Tonix Pharmaceuticals Holding? The ISIN recorded for Tonix Pharmaceuticals Holding Corp. is US8902608392. Does aibio.space cover Tonix Pharmaceuticals Holding? aibio.space lists Tonix Pharmaceuticals Holding Corp. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Tonix Pharmaceuticals Holding incorporated? SEC records list its state or country of incorporation as NV. What does Tonix Pharmaceuticals Holding develop? Tonix Pharmaceuticals is a fully integrated biopharmaceutical company commercializing and developing innovative therapies for central nervous system disorders, immunology, infectious diseases and rare diseases. Its first internally developed product, TONMYA (cyclobenzaprine HCl sublingual tablets), was approved by the FDA in August 2025 for fibromyalgia in adults and launched on November 17, 2025. What is TONMYA (cyclobenzaprine HCl sublingual tablets) from Tonix Pharmaceuticals Holding? TONMYA (cyclobenzaprine HCl sublingual tablets): Non-opioid analgesic for fibromyalgia in adults Stage: approved in the US. What is Zembrace SymTouch (sumatriptan injection) from Tonix Pharmaceuticals Holding? Zembrace SymTouch (sumatriptan injection): Acute migraine treatment Stage: approved in the US. What was Tonix Pharmaceuticals Holding's revenue last year? $13.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Tonix Pharmaceuticals Holding profitable? Tonix Pharmaceuticals Holding Corp. reported a net loss of $124.0 million for the fiscal year ended Dec 31, 2025, and used $99.8 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Tonix Pharmaceuticals Holding Members talk about Tonix Pharmaceuticals Holding (TNXP). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Tonix Pharmaceuticals Holding, newest first. Each line links the filing it comes from. 1. 2026-05-07 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1430306/000199937126010226/tnxp-8k_050726.htm) 2. 2026-03-30 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1430306/000199937126007108/tnxp-def14a_050726.htm) 3. 2026-03-20 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1430306/000199937126006640/tnxp-pre14a_032026.htm) 4. 2026-03-18 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1430306/000199937126006169/tonix-8k_031826.htm) 5. 2026-03-12 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1430306/000199937126005730/tnxp-10k_123125.htm) 6. 2025-12-29 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1430306/000199937125021282/tnxp_424b5-122925.htm) 7. 2025-11-21 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1430306/000199937125018392/tnxp-8k_112125.htm) 8. 2025-11-18 Financings Announced a share repurchase program. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1430306/000199937125018108/tnxp-8k_111825.htm) 9. 2025-06-11 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1430306/000199937125007625/tnxp-8k.htm) 10. 2025-05-08 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1430306/000199937125005717/tnxp-8k_050825.htm) 11. 2025-03-31 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1430306/000199937125003527/tonix_def14a-050825.htm) 12. 2025-03-21 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1430306/000199937125002999/tonix_pre14a-050825.htm) 13. 2025-02-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1430306/000199937125001802/tnxp-8k_022025.htm) 14. 2025-02-07 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1430306/000199937125001293/ex99-01.htm) 15. 2025-02-03 Listings Reported a reverse stock split. SEC Form 8-K (Items 1.02,2.02,3.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1430306/000199937125001105/ex99-01.htm) 16. 2024-12-20 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1430306/000183988224046554/tonix-424b5_122024.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:TNXP on TradingView](https://www.tradingview.com/symbols/NASDAQ-TNXP/). ## SEC filings and registration - **SEC name**: Tonix Pharmaceuticals Holding Corp. - **CIK**: 1430306 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: TNXP (Nasdaq) - **State or country of incorporation**: NV - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NJ, 07922 - **Phone**: 212-980-9155 - **Shares outstanding**: 17,151,024 as of 2026-08-07 (10-Q filed 2026-08-10) - **Former names**: TAMANDARE EXPLORATIONS INC. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1430306/000149315226047139/form8-k.htm) filed 2026-10-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1430306/000149315226045603/form8-k.htm) filed 2026-10-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1430306/000149315226043644/form8-k.htm) filed 2026-09-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1430306/000149315226041689/form8-k.htm) filed 2026-09-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1430306/000149315226039000/form8-k.htm) filed 2026-08-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/1430306/000199937126017452/tnxp-10q_063026.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1430306/000149315226036740/form8-k.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1430306/000149315226035741/form8-k.htm) filed 2026-08-03 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001430306), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Tonix Pharmaceuticals Holding Corp. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker TNXP, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Tonix Pharmaceuticals Holding Corp. - **Ticker**: TNXP - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US8902608392 - **Other listed symbols**: LS:A40VM0; LSX:A40VM0 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-TNXP/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/tonix-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Tonix Pharmaceuticals Holding (TNXP) news: lawsuit", 2026-10-31, https://aibio.space/companies/tonix-pharmaceuticals/